News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Michael Murphy, MD, PhD

Advertisement

Chief Medical and Scientific Officer, Worldwide Clinical Trials

Articles by Michael Murphy, MD, PhD

Your Phase III Clinical Protocol Is Your Initial Product Launch

ByHarris Kaplan,Michael Murphy, MD, PhD
January 30th 2026

How demand-driven development will help new products be more successful.

Advertisement

Latest Updated Articles

  • Your Phase III Clinical Protocol Is Your Initial Product Launch
    Your Phase III Clinical Protocol Is Your Initial Product Launch

    January 30th 2026



Advertisement
Advertisement

Trending on PharmExec

1

President Trump Imposes 100% Tariffs on Branded Pharmaceuticals

2

The New Antitrust Era: Why CVS-Style Healthcare Integration is Now the FTC’s Primary Target

3

Why ‘Boring’ AL Could Save Healthcare When the Bubble Bursts

4

Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava

5

Pharmaceutical Executive Daily: Leadership Turnover Under Trump Administration

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us